Detail akcie Alaunos Rg online

Business Summary: Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Alaunos Therapeutics Inc revenues decreased 67% to $2K. Net loss decreased 17% to $3.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Other General and Administrative decrease of 41% to $1.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.46 to -$1.83.